Top

Published in:

01-01-2022 | Dapagliflozin | Short Communication

Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials

Authors: Fotios Barkas, Georgia Anastasiou, Haralampos Milionis, Evangelos Liberopoulos

Published in: Diabetology International | Issue 1/2022

Abstract

The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76–0.95, p = 0.004; I² = 0, p = 0.48).

Available only for authorised users

Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–44. https://doi.org/10.1016/j.jacbts.2020.02.004.CrossRefPubMedPubMedCentral

Patoulias D, Papadopoulos C, Boulmpou A, Doumas M. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors; implications for COVID19 pandemic. Diabetes Obes Metab. 2021. https://doi.org/10.1111/dom.14359.CrossRefPubMedPubMedCentral

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28. https://doi.org/10.1056/NEJMoa2030183.CrossRefPubMed

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.CrossRefPubMed

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.CrossRefPubMed

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925.CrossRefPubMed

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. https://doi.org/10.1056/NEJMoa2022190.CrossRefPubMed

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.CrossRefPubMed

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

10.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRef

11.

Kosiborod M, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, et al. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: design and rationale for the DARE-19 study. Diabetes Obes Metab. 2020. https://doi.org/10.1111/dom.14296.CrossRefPubMedPubMedCentral

12.

Scheen AJ. SGLT2 inhibition during the COVID-19 epidemic: friend or foe? Diabetes Metab. 2020;46(5):343–4. https://doi.org/10.1016/j.diabet.2020.06.003.CrossRefPubMedPubMedCentral

13.

Lee YJ, Kim MO, Ryu JM, Han HJ. Regulation of SGLT expression and localization through Epac/PKA-dependent caveolin-1 and F-actin activation in renal proximal tubule cells. Biochim Biophys Acta. 2012;1823(4):971–82. https://doi.org/10.1016/j.bbamcr.2011.12.011.CrossRefPubMed

14.

Barkas F, Milionis H, Anastasiou G, Liberopoulos E. Statins and PCSK9 inhibitors: what is their role in coronavirus disease 2019? Med Hypotheses. 2021. https://doi.org/10.1016/j.mehy.2020.110452.CrossRefPubMed

15.

Αnastasiou G, Hatziagelaki E, Liberopoulos E. Could dapagliflozin attenuate COVID-19 progression in high-risk patients with or without diabetes? Behind DARE-19 concept. J Cardiovasc Pharmacol. 2021. https://doi.org/10.1097/FJC.0000000000001011.CrossRef

16.

Sainsbury C, Wang J, Gokhale K, Acosta-Mena D, Dhalla S, Byne N, et al. Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study. Diabetes Obes Metab. 2021;23(1):263–9. https://doi.org/10.1111/dom.14203.CrossRefPubMed

17.

Perez-Belmonte LM, Torres-Pena JD, Lopez-Carmona MD, Ayala-Gutierrez MM, Fuentes-Jimenez F, Huerta LJ, et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med. 2020;18(1):359. https://doi.org/10.1186/s12916-020-01832-2.CrossRefPubMedPubMedCentral

18.

Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9(5):293–303. https://doi.org/10.1016/S2213-8587(21)00050-4.CrossRefPubMedPubMedCentral

19.

Lu IN, Kulkarni S, Fisk M, Kostapanos M, Banham-Hall E, Kadyan S, et al. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):690. https://doi.org/10.1186/s13063-020-04618-2.CrossRefPubMedPubMedCentral

20.

Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22(10):1935–41. https://doi.org/10.1111/dom.14057.CrossRef

Title: Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials
Authors: Fotios Barkas
Georgia Anastasiou
Haralampos Milionis
Evangelos Liberopoulos
Publication date: 01-01-2022
Publisher: Springer Singapore
Keywords: Dapagliflozin
Empagliflozin
Heart Failure
Pneumonia
Canagliflozin
Ertugliflozin
Published in: Diabetology International / Issue 1/2022
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-021-00515-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Japanese Type 1 Diabetes Database Study (TIDE-J): rationale and study design

Correction to: Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity

Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial

Hypoglycemic coma in an elderly adult switched from twice-daily vildagliptin to once-daily glimepiride to improve drug adherence

Variables associated with adherence to the treatment of type 2 diabetes mellitus among elderly people

Electrolyzed hydrogen-rich water for oxidative stress suppression and improvement of insulin resistance: a multicenter prospective double-blind randomized control trial

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials